Together, these cell line, patient and PDTX data indicate that VM is enriched in the aggressive subtypes of human tumors and that combined tumor-endothelial and core FOXC2-target gene expression can identify VM proficient tumors. The gene discussed is FOXC2; the disease is neoplasm.